The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy?, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.

摘要

As renal or hepatic function decreased, oxycodone Cmax and AUC(0-t) were up to approximately twofold higher following single, oral doses of extended-release Remoxy. AEs were those typically reported for opioids. Lower doses of Remoxy may thus be safely prescribed to subjects with renal or hepatic impairment.